| Dr Sierra Christine Beck, MD | |
|
531 Asbury Circle Annex, Suite N340, Atlanta, GA 30322 | |
| (404) 616-4620 | |
| (404) 778-2630 |
| Full Name | Dr Sierra Christine Beck |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 531 Asbury Circle Annex, Atlanta, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275796815 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 65635 (Georgia) | Primary |
| 207P00000X | Emergency Medicine | A110954 (California) | Secondary |
| Entity Name | The Emory Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396798229 PECOS PAC ID: 8820901408 Enrollment ID: O20031110000503 |
News Archive
A new study published in Chemrxiv in April 2020 describes the identification of 64 compounds that could potentially be inhibitors of replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 disease pandemic. The research was carried out using a pharmacophore model of an essential viral enzyme, mining data from the Food and Drug Administration (FDA) database of conformations of approved drugs.
Screening for Mental Health, Inc., the leading nonprofit provider of online and in-person mental health screening programs, today released results from a follow-up study of participants in the 2008 National Depression Screening Day® (NDSD) online program.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Cancer patients with blood clots - which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients - gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.
› Verified 6 days ago
| Entity Name | Emory Medical Care Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063452381 PECOS PAC ID: 4981501814 Enrollment ID: O20031217000968 |
News Archive
A new study published in Chemrxiv in April 2020 describes the identification of 64 compounds that could potentially be inhibitors of replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 disease pandemic. The research was carried out using a pharmacophore model of an essential viral enzyme, mining data from the Food and Drug Administration (FDA) database of conformations of approved drugs.
Screening for Mental Health, Inc., the leading nonprofit provider of online and in-person mental health screening programs, today released results from a follow-up study of participants in the 2008 National Depression Screening Day® (NDSD) online program.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Cancer patients with blood clots - which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients - gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sierra Christine Beck, MD 531 Asbury Circle- Annex, Suite N340 Emory Healthcare, Atlanta, GA 30322 Ph: (404) 616-4620 | Dr Sierra Christine Beck, MD 531 Asbury Circle Annex, Suite N340, Atlanta, GA 30322 Ph: (404) 616-4620 |
News Archive
A new study published in Chemrxiv in April 2020 describes the identification of 64 compounds that could potentially be inhibitors of replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 disease pandemic. The research was carried out using a pharmacophore model of an essential viral enzyme, mining data from the Food and Drug Administration (FDA) database of conformations of approved drugs.
Screening for Mental Health, Inc., the leading nonprofit provider of online and in-person mental health screening programs, today released results from a follow-up study of participants in the 2008 National Depression Screening Day® (NDSD) online program.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Cancer patients with blood clots - which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients - gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.
› Verified 6 days ago
Dr. Benjamin Aaron Levy, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5665 New Northside Dr Nw, Suite 200, Atlanta, GA 30328 Phone: 770-874-5400 | |
Essi I Peers, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5665 New Northside Dr Ste 200, Atlanta, GA 30328 Phone: 770-874-5400 | |
Prince N Martin, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5665 Peachtree Dunwoody Rd, Atlanta, GA 30342 Phone: 678-843-7001 | |
Melissa H White, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 Jesse Hill Jr Dr Se, Atlanta, GA 30303 Phone: 404-616-4307 Fax: 404-616-8022 | |
John H Lloyd, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1358 Middlesex Ave Ne, Atlanta, GA 30306 Phone: 404-944-7563 | |
Dr. Vida M. Reklaitis, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Johnson Ferry Rd Ne, Atlanta, GA 30342 Phone: 404-851-6936 Fax: 404-851-6024 | |
Dr. Steven M Joyce, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2292 Peachtree Rd., Nw, Atlanta, GA 30309 Phone: 801-558-7791 |